利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.021 秒)

    Methodologies and Reagents for Detecting Fibrinolysis and Hyperfibrinolysis
    1.
    发明申请
    Methodologies and Reagents for Detecting Fibrinolysis and Hyperfibrinolysis 有权
    用于检测纤维蛋白溶解和超纤维蛋白溶解的方法和试剂

    公开(公告)号：US20150316565A1

    公开(公告)日：2015-11-05

    申请号：US14270269

    申请日：2014-05-05

    申请人： Haemonetics Corporation ,  The Regents of the University of Colorado

    发明人： Michael P. Chapman ,  Ernest E. Moore ,  Katherine M. Norem

    IPC分类号： G01N33/86

    CPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N33/49

    摘要： In some embodiments, the invention provides methods for detecting fibrinolysis or hyperfibrinolysis in a blood sample from a patient. The method includes subjecting a first portion of a blood sample comprising reduced platelet function to viscoelastic analysis in the absence of an inhibitor of fibrinolysis to obtain the coagulation characteristic of the first portion at the time point; and subjecting a second portion of the blood sample comprising reduced platelet function to viscoelastic analysis in the presence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the second portion at a time point; wherein a difference between the coagulation characteristic of the first portion and the coagulation characteristic of the second portion indicates fibrinolysis or hyperfibrinolysis in the blood sample.In some embodiments, the invention also provides a container adapted for detecting hyperfibrinolysis or fibrinolysis in a blood sample using viscoelastic analysis comprising an interior having a coating comprises an inhibitor of fibrinolysis.

    摘要翻译： 在一些实施方案中，本发明提供了用于在来自患者的血液样品中检测纤维蛋白溶解或超纤维蛋白溶解的方法。 该方法包括：在不存在纤维蛋白溶解抑制剂的情况下使包含减少的血小板功能的血液样品的第一部分进行粘弹性分析，以获得在该时间点的第一部分的凝结特性; 并且在纤维蛋白溶解抑制剂存在的情况下使包含还原血小板功能的血液样品的第二部分进行粘弹性分析，以在时间点获得第二部分的凝固特征; 其中第一部分的凝固特性与第二部分的凝固特性之间的差异表示血液样品中的纤维蛋白溶解或超纤维蛋白溶解。 在一些实施方案中，本发明还提供了适用于使用粘弹性分析检测血液样品中的超纤维蛋白溶解或纤维蛋白溶解的容器，其包含具有包含纤维蛋白溶解抑制剂的涂层的内部。

    Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis in a blood sample using viscoelastic analysis
    2.
    发明授权
    Methodologies and reagents for detecting fibrinolysis and hyperfibrinolysis in a blood sample using viscoelastic analysis 有权
    使用粘弹性分析检测血液样品中的纤维蛋白溶解和超纤维蛋白溶解的方法和试剂

    公开(公告)号：US09354243B2

    公开(公告)日：2016-05-31

    申请号：US14270269

    申请日：2014-05-05

    申请人： Haemonetics Corporation ,  The Regents of the University of Colorado, a body corporate

    发明人： Michael P. Chapman ,  Ernest E. Moore ,  Katherine M. Norem

    IPC分类号： G01N33/86

    CPC分类号： G01N33/86 ,  C12Q1/56 ,  G01N33/49

    摘要： In some embodiments, the invention provides methods for detecting fibrinolysis or hyperfibrinolysis in a blood sample from a patient. The method includes subjecting a first portion of a blood sample comprising reduced platelet function to viscoelastic analysis in the absence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the first portion at a time point; and subjecting a second portion of the blood sample comprising reduced platelet function to viscoelastic analysis in the presence of an inhibitor of fibrinolysis to obtain a coagulation characteristic of the second portion at the time point; wherein a difference between the coagulation characteristic of the first portion and the coagulation characteristic of the second portion indicates fibrinolysis or hyperfibrinolysis in the blood sample.

    摘要翻译： 在一些实施方案中，本发明提供了用于在来自患者的血液样品中检测纤维蛋白溶解或超纤维蛋白溶解的方法。 所述方法包括在不存在纤维蛋白溶解抑制剂的情况下使包含减少的血小板功能的血液样品的第一部分进行粘弹性分析，以在时间点获得第一部分的凝结特征; 并且在纤维蛋白溶解抑制剂存在的情况下使包含减少的血小板功能的血液样品的第二部分进行粘弹性分析，以在该时间点获得第二部分的凝结特征; 其中第一部分的凝固特性与第二部分的凝固特性之间的差异表示血液样品中的纤维蛋白溶解或超纤维蛋白溶解。

    Use of Viscoelastic Analysis for Predicting Massive Hemorrhage
    5.
    发明申请
    Use of Viscoelastic Analysis for Predicting Massive Hemorrhage 审中-公开

    公开(公告)号：US20180011116A1

    公开(公告)日：2018-01-11

    申请号：US15664565

    申请日：2017-07-31

    申请人： The Regents of the University of Colorado, a body corporate

    发明人： Michael P. Chapman

    IPC分类号： G01N33/86 ,  A61B5/02

    CPC分类号： G01N33/86 ,  A61B5/02042 ,  A61B2505/05 ,  G01N33/4905 ,  G01N2800/22 ,  G01N2800/50

    摘要： The invention provides methods for identifying a patient as likely to have an onset of massive hemorrhage. In one embodiment, the invention provides a method for identifying a patient as likely to have an onset of massive hemorrhage, the method comprising measuring at least one of first coagulation characteristic parameter reflective of a clotting time in a sample of blood of the patient, a second coagulation characteristic parameter reflective of clot formation in a sample of blood of the patient using the viscoelastic assay to obtain a second result; a third coagulation characteristic parameter reflective of clot strength in a sample of blood of the patient using the viscoelastic assay to obtain a third result; and a fourth coagulation characteristic parameter reflective of clot lysis in a sample of blood of the patient using the viscoelastic assay to obtain a fourth result; wherein, a positive for at least one of the first result, second result, third result and fourth result identifies the patient as likely to have an onset of massive hemorrhage.

    Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent
    7.
    发明授权
    Identification of novel disease states using viscoelastic analysis in the presence of a thrombolytic agent 有权

    公开(公告)号：US11137409B2

    公开(公告)日：2021-10-05

    申请号：US15524095

    申请日：2015-11-05

    申请人： The Regents of the University of Colorado, a body corporate

    发明人： Michael P. Chapman ,  Hunter B. Moore ,  Eduardo Gonzalez Barreda ,  Ernest E. Moore

    IPC分类号： G01N33/86 ,  A61K38/36 ,  C12Q1/56

    摘要： In some embodiments, the invention provides methods for detecting an aberrant fibrinolysis condition in a patient. The method includes subjecting a blood sample from the patient to a viscoelastic analysis in the presence of a known amount of a thrombolytic agent, to obtain a coagulation characteristic value of the patient; and comparing the coagulation characteristic value of the patient to a coagulation characteristic value of a healthy individual, the coagulation characteristic value of the healthy individual obtained by subjecting a blood sample from a healthy individual to the viscoelastic analysis in the presence of the known amount of the thrombolytic agent, wherein a difference in the coagulation characteristic value of the patient as compared to the coagulation characteristic value of the healthy individual identifies the patent as having aberrant fibrinolysis. In some embodiments, the invention also provides a container adapted for detecting an aberrant fibrinolysis condition in a blood sample using viscoelastic analysis comprising an interior having a coating comprising a thrombolytic agent.